



# 23. ANNUAL SCIENTIFIC MEETING

12.03. - 13.03.2026  
FRANKFURT /MAIN


Prof. Dr. Sibylle Loibl




# Kumulative Rekrutierung



# Publikationen



# Publikationen



# Publikationen

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)\*

Original Reports | Breast Cancer

## Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer

Fabio Conforti, MD<sup>1,2</sup>; Valentina Nekjudova, PhD<sup>3</sup>; Isabella Sala, MSc<sup>4</sup>; Roberto Ascarelli, PhD<sup>5</sup>; Christine Solbach, MD, PhD<sup>6</sup>; Michael Untch, MD, PhD<sup>7</sup>; Carsten Denkert, MD<sup>8</sup>; Vincenzo Bagnardi, PhD<sup>9</sup>; Laura Pala, MD<sup>10</sup>; Peter A. Fasching, MD<sup>11</sup>; Andreas Schneeweiss, MD, PhD<sup>12</sup>; Hans-Joachim Lück, MD<sup>13</sup>; Eleonora Pagan, PhD<sup>14</sup>; Tommaso De Pas, MD<sup>15</sup>; Marion van Mackelenbergh, MD, PhD<sup>16</sup>; Jens Huober, MD<sup>17</sup>; Volkmar Müller, MD<sup>18</sup>; Theresa Link, MD<sup>19</sup>; Thomas Kam, MD, PhD<sup>20</sup>; Mattes Reinisch, MD<sup>21</sup>; Frederik Marmé, MD, PhD<sup>22</sup>; Vesna Bjelic-Radisic, MD, PhD<sup>23</sup>; Christian Schem, MD, PhD<sup>24</sup>; Andreas Hartkopf, MD<sup>25</sup>; Elmar Sticker, MD<sup>26</sup>; Claus Hahusch, MD<sup>27</sup>; Jens-Uwe Blohmer, MD, PhD<sup>28</sup>; Tanja Fehm, MD, PhD<sup>29</sup>; Kerstin Rhiem, MD<sup>30</sup>; Johannes Holtschmidt, MD<sup>31</sup>; Richard D. Gelber, PhD<sup>32</sup>; and Sibylle Loibl, PhD<sup>33</sup>

DOI: <https://doi.org/10.1200/JCO.24.01360>

## Impact of the ONCOBIOME network in cancer microbiome research

Laurence Zitvogel, Lisa Derosa, Bertrand Routy, Sibylle Loibl, Lucie Heinzerling, J. Jolanda M. de Vries,

Lars Engstrand, ONCOBIOME Network, Nicola Segata & Guido Kroemer

Nature Medicine 31, 1085–1098 (2025) | [Cite this article](#)

5966 Accesses | 13 Citations | 26 Altmetric | [Metrics](#)

GBG

GERMAN  
BREAST  
GROUP

23. ANNUAL SCIENTIFIC MEETING

Der Inhalt ist urheberrechtlich geschützt und liegt in der Verantwortung des Autors. Eine Weiterverwendung ist nur mit Genehmigung zulässig.  
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / 2026

npj | breast cancer

Published in partnership with the Breast Cancer Research Foundation

Article



<https://doi.org/10.1038/s41523-025-00758-3>

## Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

Check for updates

Kristin Galan<sup>1</sup>, Moritz Gleitsman<sup>2</sup>, Julia Rey<sup>3</sup>, Christine Solbach<sup>4</sup>, Isabell Witzel<sup>5</sup>, Thomas Kam<sup>6</sup>, Sabine Schmittlocher<sup>7</sup>, Christian Schem<sup>8</sup>, Andreas Schneeweiss<sup>9</sup>, Bruno Sinn<sup>10</sup>, Tanja Fehm<sup>11</sup>, Carsten Denkert<sup>12</sup>, Peter Fasching<sup>13</sup>, Anne-Sophie Litzmeyer<sup>14</sup>, Frederik Marmé<sup>15</sup>, Paul Jank<sup>16</sup>, Volkmar Müller<sup>17</sup>, Sabine Seiler<sup>18</sup>, Elmar Sticker<sup>19</sup>, Olaf Ortmann<sup>20</sup>, Marion van Mackelenbergh<sup>21</sup>, Valentina Nekjudova<sup>22</sup>, Johannes Holtschmidt<sup>23</sup> & Sibylle Loibl<sup>24</sup>

## Cancer Cell

### Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping

Graphical abstract



Authors

Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Kam, Johannes Holtschmidt, Valentina Nekjudova, Sibylle Loibl

CLINICAL CANCER RESEARCH | RESEARCH BRIEFS: CLINICAL TRIAL BRI

## Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter<sup>1,2</sup>, Werner Schroth<sup>1</sup>, Matthew P. Goetz<sup>3</sup>, Roman Tremmel<sup>1</sup>, Svitlana Igel<sup>1</sup>, Elke Schaeffeler<sup>1,2</sup>, Simon Jäger<sup>1,4</sup>, Sibylle Loibl<sup>5,6</sup>, Andreas Gerteis<sup>7</sup>, Lena Pfaff<sup>7</sup>, Christina Bechtner<sup>8</sup>, Denise Wrobel<sup>9</sup>, Ilka Bernhöft<sup>10</sup>, The German TAMENDOX Clinicians Group<sup>11</sup>, Imma Fischer<sup>12</sup>, Christoph Meisner<sup>12</sup>, Michael Block<sup>13</sup>, Hiltrud Brauch<sup>12,14,15,16</sup>, and Matthias Schwab<sup>2,14,15,16,17,18</sup>

Article

ESMO

GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

ANNALS OF  
ONCOLOGY

BRIEF TRIAL UPDATES

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy\*

S. Loibl<sup>1,2</sup>, M. Martin<sup>3,4</sup>, H. Bonnefoi<sup>5</sup>, M. Untch<sup>6</sup>, S.-B. Kim<sup>7</sup>, H. D. Bear<sup>8</sup>, J. A. Garcia-Saenz<sup>9</sup>, M. Melé Olive<sup>10</sup>, N. Mc Carthy<sup>11</sup>, K. Gelmon<sup>12</sup>, C. M. Kelly<sup>13</sup>, S.-A. Im<sup>14,15,16</sup>, T. Reimer<sup>17</sup>, M. Martinez-Janez<sup>18</sup>, Z. Zhang<sup>19</sup>, M. Toli<sup>20</sup>, L. Provencher<sup>21,22</sup>, H. S. Rugo<sup>23</sup>, M. Gnant<sup>24</sup>, A. Makris<sup>25</sup>, A. Anton Torres<sup>26</sup>, N. Hirmas<sup>27</sup>, J. Holtschmidt<sup>28</sup>, V. Nekjudova<sup>29</sup> & F. Marmé<sup>30</sup>

Signal Transduction and Targeted Therapy

[www.nature.com/sigtrans](https://www.nature.com/sigtrans)

ARTICLE OPEN

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

ESMO

GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

ESMO  
OPEN  
SCIENCE FOR OPTIMAL  
CANCER CARE

ORIGINAL ARTICLE

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)

T. Link<sup>1,2</sup>, M. Reinisch<sup>3</sup>, M. Just<sup>4</sup>, M. Untch<sup>5</sup>, N. Filmann<sup>6</sup>, O. Stötter<sup>7</sup>, C. Denkert<sup>8</sup>, V. Bjelic-Radisic<sup>9</sup>, P. Wimberger<sup>1</sup>, M. Thill<sup>10</sup>, K. Rhiem<sup>11</sup>, J. Huober<sup>12</sup>, C. Solbach<sup>13</sup>, C. Hahusch<sup>14</sup>, K. Engels<sup>15</sup>, P. A. Fasching<sup>16</sup>, A. Schneeweiss<sup>17</sup>, V. Nekjudova<sup>18</sup>, J. Holtschmidt<sup>19</sup>, J.-U. Blohmer<sup>20</sup> & S. Loibl<sup>21,22</sup>

# Publikationen im New Engl J Med

DB05/TruDy

The NEW ENGLAND JOURNAL of MEDICINE

## ORIGINAL ARTICLE

### Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

S. Loibl,<sup>1,2</sup> Y.H. Park,<sup>3</sup> Z. Shao,<sup>4</sup> C.-S. Huang,<sup>5</sup> C. Barrios,<sup>6</sup> J. Abraham,<sup>7</sup> A. Prat,<sup>8,9</sup> N. Niikura,<sup>10</sup> S.-A. Im,<sup>11</sup> W. Li,<sup>12</sup> H. Li,<sup>13</sup> Y. Wang,<sup>14</sup> H. Yao,<sup>15</sup> S.-B. Kim,<sup>16</sup> C. Geng,<sup>17</sup> W. Rodriguez Pantigoso,<sup>18</sup> F.J. Ramirez Godinez,<sup>19</sup> C. Song,<sup>20</sup> Y. Ching Chang,<sup>21</sup> A. Antoniazzi,<sup>22</sup> S.-C. Chen,<sup>23</sup> Z. Li,<sup>24</sup> Z. Nowecki,<sup>25</sup> J. Lim,<sup>26</sup> E. Mathias,<sup>27</sup> Y. Sato,<sup>28</sup> W. Lu,<sup>29</sup> H. Abdel-Monem,<sup>30</sup> M. Untch,<sup>31</sup> and C.E. Geyer, Jr.,<sup>32,33</sup> for the DESTINY-Breast05 Trial Investigators\*

The NEW ENGLAND JOURNAL of MEDICINE

## ORIGINAL ARTICLE

### Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

S.M. Tolaney,<sup>1</sup> Z. Jiang,<sup>2</sup> Q. Zhang,<sup>3</sup> R. Barroso-Sousa,<sup>4</sup> Y.H. Park,<sup>5</sup> M.F. Rimawi,<sup>6</sup> C. Saura,<sup>7</sup> A. Schneeweiss,<sup>8</sup> M. Toi,<sup>9</sup> Y.S. Chae,<sup>10</sup> Y. Kemal,<sup>11</sup> M. Chaudhari,<sup>12</sup> M.A.N. Şendur,<sup>13</sup> T. Yamashita,<sup>14</sup> M. Casalnuovo,<sup>15</sup> M.A. Danso,<sup>16,17</sup> J. Liu,<sup>18</sup> J. Shetty,<sup>19</sup> P. Herbolzheimer,<sup>19</sup> and S. Loibl,<sup>20,21</sup> for the DESTINY-Breast09 Trial Investigators\*

Patina

The NEW ENGLAND JOURNAL of MEDICINE

## ORIGINAL ARTICLE

### Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer

O. Metzger,<sup>1</sup> S. Mandrekar,<sup>2</sup> S. Goel,<sup>3</sup> J. Gligorov,<sup>4,5</sup> E. Lim,<sup>6</sup> E. Ciruelos,<sup>7</sup> S. Loibl,<sup>8</sup> T. Dockter,<sup>9</sup> X. González Farré,<sup>9</sup> P.A. Francis,<sup>9</sup> F. Lynce,<sup>9</sup> J. Lanzillotti,<sup>10</sup> C. DuFrane,<sup>10</sup> A. Wall,<sup>11</sup> C. Strand,<sup>11</sup> I. Krop,<sup>11</sup> I. Vaz-Luis,<sup>12</sup> D. Tripathy,<sup>13</sup> S. Loi,<sup>14</sup> A. Prat,<sup>14</sup> M. Goetz,<sup>15</sup> S. Escrivá-de-Romaní,<sup>15</sup> D. Porter,<sup>16</sup> J. Spoenlein,<sup>17</sup> D.G. Stover,<sup>18</sup> S. Sardesai,<sup>18</sup> P. Heudel,<sup>19</sup> M. Koehler,<sup>20</sup> C. Huang Bartlett,<sup>21</sup> A. Holynsky,<sup>21</sup> P. Gopalakrishna,<sup>21</sup> E. Gauthier,<sup>21</sup> S. Delaloge,<sup>22</sup> K. Miller,<sup>22</sup> E.P. Winer,<sup>23</sup> L. Gianni,<sup>23</sup> A.H. Partridge,<sup>24</sup> A. DeMichele,<sup>24</sup> and L.A. Carey<sup>25</sup>

KATHERINE

The NEW ENGLAND JOURNAL of MEDICINE

## ORIGINAL ARTICLE

### Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, Jr., M.D., Michael Untch, M.D., Ph.D.,  
Chun-Sheng Huang, M.D., Ph.D., M.P.H., Max S. Mano, M.D., Ph.D.,  
Eleftherios P. Mamounas, M.D., M.P.H., Norman Wolmark, M.D.,  
Priya Rastogi, M.D., Andreas Schneeweiss, M.D., Andres Redondo, M.D., Ph.D.,  
Hans H. Fischer, M.D., Véronique D'Hondt, M.D., Ph.D., Alison K. Conlin, M.D.,  
Valentina Guarneri, M.D., Ph.D., Irene L. Wapnir, M.D.,  
Christian Jackisch, M.D., Ph.D., Claudia Arce-Salinas, M.D., Ph.D.,  
Peter A. Fasching, M.D., Michael P. DiGiorgio, M.D., Ph.D., John P. Crown, M.D.,  
Pia Wuelfling, M.D., Zhimin Shao, M.D., Elena Rota Cernomki, M.D.,  
Henri R. Bonneau, M.D., Bryan T. Hennessy, M.D., Ljiljana Stamatovic, M.D., Ph.D.,  
Hugo Castro-Salgado, M.D., Adam M. Brufsky, M.D., Ph.D., Adam Knott, Ph.D.,  
Asna Siddiqui, Ph.D., Chiara Lambertini, Ph.D., Thomas Boulet, M.S.,  
Beatrice Nyawira, M.D., Eleonora Restuccia, M.D., and Sibylle Loibl, M.D., Ph.D.,  
for the KATHERINE Study Group\*

INSEMA

The NEW ENGLAND  
JOURNAL of MEDICINE

ESTABLISHED IN 1812

MARCH 13/20, 2025

VOL. 392 NO. 11

### Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial

T. Reimer,<sup>1</sup> A. Stachs,<sup>1</sup> K. Veselinovic,<sup>2</sup> T. Kühn,<sup>3</sup> J. Heil,<sup>4,5</sup> S. Polata,<sup>6</sup> F. Marmé,<sup>7</sup> T. Müller,<sup>8</sup> G. Hildebrandt,<sup>9</sup> D. Krug,<sup>10,11</sup> B. Ataseven,<sup>12</sup> R. Reitsamer,<sup>13</sup> S. Ruth,<sup>14</sup> C. Denkert,<sup>15</sup> I. Bekes,<sup>16</sup> D.-M. Zahm,<sup>17</sup> M. Thill,<sup>18</sup> M. Golatta,<sup>19</sup> J. Holschmidt,<sup>20</sup> M. Knauer,<sup>20</sup> V. Nekljudova,<sup>21</sup> S. Loibl,<sup>21</sup> and B. Gerber<sup>21</sup>

The NEW ENGLAND JOURNAL of MEDICINE

## ORIGINAL ARTICLE

### Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

Komal L Jhaveri, M.D.,<sup>1,2</sup> Seock-Ah Im, M.D., Ph.D.,<sup>3</sup> Cristina Saura, M.D., Ph.D.,<sup>4</sup> Sibylle Loibl, M.D., Ph.D.,<sup>5,6</sup> Kevin Kalinsky, M.D.,<sup>7</sup> Peter Schmid, M.D., Ph.D.,<sup>8</sup> Sherene Loi, M.D., Ph.D.,<sup>9,10</sup> Eirini Thanopoulou, M.D., Ph.D.,<sup>11</sup> Noopur Shankar, M.D., Ph.D.,<sup>12</sup> Yanling Jin, Ph.D.,<sup>13</sup> Thomas J. Stout, Ph.D.,<sup>12</sup> Tiffany D. Clark, Ph.D.,<sup>12</sup> Chunyan Song, M.D.,<sup>12</sup> Dejan Juric, M.D.,<sup>14</sup> and Nicholas C. Turner, M.D., Ph.D.<sup>15</sup>

# Kongresse

## 2025

- SABCS
  - 2 Poster
  - 7 Oral Presentations
- ESMO
  - 1 Poster
  - 1 Oral Presentation
- DGHO
  - 2 Poster
- DGS
  - 1 Poster



#womeninscience #frauenpower

# Kongresse

## 2025


- ESMO Breast Cancer
  - 3 Poster
  - 1 Oral Presentation
- SATURN 3
  - 1 Poster
- JBCS
  - 1 Oral Presentation

## 2026

- ESMO Breast Cancer
  - 5 Poster
  - 1 Oral Presentation
- ESMO
- DGS
- ASCO
  - 4 Beiträge, tba
- SABCS



# Netzwerk Deutschland





**2025**

waren 340 Zentren aktiv in  
aktuelle Studien eingebunden


**2026**

- Freie Flächen erschließen
- Niedergelassene Praxen abholen


# Subboards



# Subboards



# Subboards



# Subboards

---

## Herzlich Willkommen an unser neues Board-Mitglied!

### Subboard Neoadjuvant

Dr. med. Christian Maurer, Köln



# Wir bedanken uns bei den Sponsoren

Die GBG Forschungs GmbH wird im Rahmen des 23. Annual Scientific Meetings durch folgende pharmazeutische Unternehmen finanziell unterstützt. Auf Programm oder Inhalte der Veranstaltung haben diese keinen Einfluss. Pharmaceutical companies have provided a sponsorship to GBG Forschungs GmbH in support of the GBG 23rd Annual Scientific Meeting to cover costs associated with their package for this meeting, they have had no input in the agenda or any other content.

Platin



Gold



Silber

Silber



Supporter

Jazz Pharmaceuticals unterstützt die GBG Forschungs GmbH im Rahmen des 23. Annual Scientific Meetings finanziell, (Silber Sponsoring), ohne Einfluss auf die Agenda oder sonstige Inhalte der Veranstaltung zu nehmen. Jazz Pharmaceuticals has provided a sponsorship to GBG Forschungs GmbH in support of the GBG 23rd Annual Scientific Meeting to cover costs associated with the Silver package for this meeting but has had no input in the agenda or any other content.

Heilung durch Innovation, Kompetenz  
und Partnerschaft – führend in der  
Brustkrebs-Forschung



### 23. ANNUAL SCIENTIFIC MEETING

Der Inhalt ist urheberrechtlich geschützt und liegt in der Verantwortung des Autors. Eine Weiterverwendung ist nur mit Genehmigung zulässig.  
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / 2026

# Save the Date

---

„Wir freuen uns Sie auch 2027 wieder  
zu unserem 2- tägigen, international besetzten  
**24. Annual Scientific Meeting**  
am **12.-13.03.2027** einladen zu dürfen.“

*Prof. Dr. Sibylle Loibl*



# Join us in Vienna!



SGBCC 2027

## 20<sup>TH</sup> ST.GALLEN INTERNATIONAL BREAST CANCER CONFERENCE 2027

PRIMARY THERAPY OF PATIENTS WITH EARLY BREAST CANCER. EVIDENCE, CONTROVERSIES, CONSENSUS

17 - 20 MARCH 2027, VIENNA / AUSTRIA



[www.sg-bcc.org](http://www.sg-bcc.org)

GBG

GERMAN  
BREAST  
GROUP



23. ANNUAL SCIENTIFIC MEETING

Der Inhalt ist urheberrechtlich geschützt und liegt in der Verantwortung des Autors. Eine Weiterverwendung ist nur mit Genehmigung zulässig.  
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / 2026